Jean van Wyk

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial”.

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet(2021)10.1016/s0140-6736(21)00314-7

N/A

5.5DataRank · unranked

162 citations

Sean S. Brummel, Lauren Ziemba, Lynda Stranix‐Chibanda, Katie McCarthy, Anne Coletti +39 more

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00061-9

N/A

1.1DataRank · unranked

30 citations

Lauren Ziemba, Sean S. Brummel, Katie McCarthy, Anne Coletti, Chelsea Krotje +95 more

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes(2020)10.1097/qai.0000000000002275

N/A

0.806DataRank · unranked

214 citations

Juan Sierra Madero, José R. Arribas, Andrea Antinori, Roberto Ortiz, Amanda E. Clarke +16 more

Antiretrovirals and Weight Change: Weighing the Evidence

Clinical Infectious Diseases(2024)10.1093/cid/ciae191

N/A

0.635DataRank · unranked

68 citations

John R. Koethe, Paul E. Sax, Grace A. McComsey, Daniel R. Kuritzkes, Graeme Moyle +5 more

Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy

Clinical Infectious Diseases(2024)10.1093/cid/ciae441

N/A

0.165DataRank · unranked

2 citations

Sean S. Brummel, Muktar H. Aliyu, Lynda Stranix‐Chibanda, George Uchenna Eleje, Ifeanyichukwu U. Ezebialu +56 more

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum

Clinical Infectious Diseases(2024)10.1093/cid/ciae001

N/A

0DataRank · unranked

12 citations

Sean S. Brummel, Lauren Ziemba, Lameck Chinula, Katie McCarthy, Lee Fairlie +88 more

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad101

N/A

0DataRank · unranked

24 citations

Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal +12 more